Enovis Corp

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Enovis Corp reports robust Q4 performance and optimistic 2023 outlook

Enovis Corp's Q4 2022 earnings call highlighted strong performance, growth in key segments, and margin improvements. The company is optimistic about revenue growth in 2023 and aims for further margin expansion. Challenges include margin improvement targets and addressing analyst inquiries.

Enovis Corp reports strong Q1 results, eyes global expansion opportunities

Enovis Corp's Q1 performance reflects robust organic growth, margin expansion, and strategic acquisitions in the foot and ankle market. With a focus on innovation and international expansion, the company aims to sustain growth momentum and capitalize on market opportunities. Challenges include managing market dynamics and integrating future acquisitions effectively.

Enovis Corp reports robust Q2 performance and raises full-year guidance

Enovis Corp's Q2 performance showcased strong growth and margin expansion across segments, supported by strategic progress.
Raised full-year guidance reflects confidence in achieving organic sales growth and financial targets.
While challenges exist in market dynamics and operational efficiency, the company's strengths and opportunities position them for continued success.

Enovis Corp reports robust Q3 results, eyes growth through strategic acquisitions

Enovis Corp's Q3 performance reflects strong growth, margin improvement, and increased guidance, supported by strategic acquisitions.
The company's emphasis on integration, M&A activities, and operational efficiency positions it for sustained growth.
While challenges in maintaining growth and managing acquisitions exist, Enovis Corp's focus on opportunities for expansion and margin enhancement is promising.

Enovis Corp reports robust Q4 performance and optimistic outlook for 2024

Enovis Corp's Q4 2023 performance reflects strong revenue growth, margin expansion, and strategic acquisitions, setting the stage for a promising 2024.
The company's strengths lie in organic growth, competitive leadership, and a focus on innovation, while challenges include margin pressures and segment growth dynamics.
Opportunities abound for Enovis in market expansion, product refinement, and revenue enhancement, requiring careful navigation of challenges and external factors.
With a solid financial foundation, strategic outlook, and focus on sustainable growth, Enovis is poised for continued success and market leadership in the med tech sector.

Enovis Corp reports strong Q1 performance, eyes growth opportunities

Enovis Corp's Q1 2024 performance reflects robust revenue growth, margin improvement, and increased guidance, underpinned by strategic initiatives in product innovation and cross-selling.
While facing integration challenges and supply constraints, the company is poised to capitalize on opportunities like Arvis adoption, shoulder product launch, and margin expansion.
Analyst inquiries highlighted key areas for Enovis Corp's focus, signaling a proactive approach to addressing challenges and leveraging growth prospects in the market.

Enovis Corp (ENOV) reports strong Q2 growth despite integration challenges

Enovis Corp (ENOV) delivered robust Q2 results, showcasing revenue growth, margin improvement, and progress in acquisitions. While facing integration challenges, the company remains focused on strategic initiatives to drive future growth and enhance shareholder value.

Enovis Corp (ENOV) reports robust Q3 performance and tightens revenue guidance

Enovis Corp (ENOV) showcased strong financial performance in Q3 2024, driven by revenue growth and margin expansion across key segments.
While challenges like dissynergies and market dynamics were discussed, the company remains optimistic about future growth prospects.
Strategic strengths in business segments and a tightened revenue guidance underscore Enovis Corp's commitment to sustained performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Wilmington, DE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today announced its intention to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due 2028 (the “Notes”) in a private offering (the “Offering”). In connection with the Offering, Enovis expects to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $60 million aggregate principal amount of the Notes on the same terms and conditions.

Enovis Corporation Announces Proposed Private Offering of $400 Million of Convertible Senior Notes

Wilmington, DE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its third quarter 2023 financial results on Tuesday, November 7, 2023 at 8:00 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

Enovis to Host Third Quarter 2023 Results Conference Call on November 7th

Enovis (ENOV) is a Zacks Rank #5 (Strong Sell) has seen earnings estimates slide lower recently despite a good history of beating Zacks Consensus Estimate. This article will look at why this stock is a Zacks Rank #5 (Strong Sell) as it is the Bear of the Day.

Bear Of The Day: Enovis (ENOV)

The acquisition of LimaCorporate provides Enovis with cost synergy opportunities, access to cross-selling opportunities in Europe, new technologies (like customizable 3D printing), and solid growth. Enovis has been reporting better margins and strong growth in its Recon business, outperforming not only in the hip/knee business, but in extremities as well. I've never really embraced Enovis, but I do think the valuation is too low relative to the growth and margin opportunities here.

Enovis Making Good Choices, But Not Seeing The Rewards

Medical technology company Enovis Corp. ENOV, -0.44% said Monday it has reached an agreement to acquire LimaCorporate S.p.A., a privately held orthopedic company that specializes in restoring motion using implants, for 700 million euros ($745 million) in cash at closing and another EUR100 million in Enovis stock.

Enovis to acquire implant maker LimaCorporate for 800 million euros in cash and stock

Wilmington, DE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”), an innovation-driven, medical technology growth company, today announced a definitive agreement to acquire LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions. The acquisition has an enterprise value of approximately €800 million, consisting of a €700 million cash payment at closing and €100 million in shares of Enovis common stock.

Enovis to Acquire LimaCorporate S.p.A.

Enovis Corp , a U.S. maker of orthopedic bracing and shoe inserts, said on Monday it had agreed to acquire Italian surgical implant manufacturer LimaCorporate for about 800 million euros ($850 million), including debt.

Enovis to buy prosthetic implants maker LimaCorporate for $850 mln

New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company's growing evidence based, high tech portfolio. New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company's growing evidence based, high tech portfolio.

Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting

Enovis Corporation (NYSE:ENOV ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Investor Relations Matt Trerotola - Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Brett Fishbin - KeyBanc Kyle Rose - Canaccord Genuity Vijay Kumar - Evercore ISI Dane Reinhardt - Baird Operator Good day, and welcome to the Enovis Second Quarter 2023 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Enovis Corporation (ENOV) Q2 2023 Earnings Call Transcript

Enovis (ENOV) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.59 per share a year ago.

Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates

Wilmington, DE, Aug. 03, 2023 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 30, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Enovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook

Enovis Corporation continues to grow, with revenues increasing by 16% in the Recon part of their business, and the company's share price also growing rapidly. The company has been actively making acquisitions, including the recent purchase of Novastep, a company focusing on foot and ankle solutions, which is expected to be a key growth driver in the future. Despite potential risks such as the lack of a robotics system, Enovis is still considered a good long-term investment due to its steady growth, strong acquisitions, and expected EPS growth.

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Wilmington, DE, July 11, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its second quarter 2023 financial results on Thursday August 3, 2023 at 8:30 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

Enovis to Host Second Quarter 2023 Results Conference Call on August 3rd

Wilmington, DE, July 06, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced today that it has been recognized as one of America's Greatest Workplaces 2023 by Newsweek . Newsweek partnered with Plant-A Insights Group, a market-data research firm, to identify America's Greatest Workplaces by conducting a large-scale employer study based on over 389,000 company reviews in the United States.

Enovis™ Recognized as One of America's Greatest Workplaces 2023 by Newsweek

Wilmington, DE, June 28, 2023 (GLOBE NEWSWIRE) --  Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it closed the acquisition of Novastep®, a subsidiary of Amplitude Surgical SA (Paris: AMPLI), and global developer of clinically proven foot and ankle solutions.

Enovis™ Completes Acquisition of Novastep®

Wilmington, DE, June 02, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences in June:

Enovis to Participate in Investor Conferences in June

Enovis Corporation (NYSE:ENOV ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Investor Relations Matt Trerotola - Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Kyle Rose - Canaccord Genuity Jeff Johnson - Baird Xuyang Li - Jefferies Brett Fishbin - KeyBanc Operator Good day, and welcome to the Enovis First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note, today's event is being recorded.

Enovis Corporation (ENOV) Q1 2023 Earnings Call Transcript

Enovis (ENOV) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.37 per share a year ago.

Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates

Wilmington, DE, May 04, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended March 31, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Enovis Announces First Quarter 2023 Results

Wilmington, DE, April 13, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the “Investors” section.

Enovis to Host First Quarter 2023 Results Conference Call on May 4th

Strengthens Foot and Ankle Portfolio with Leading Minimally Invasive Surgery (MIS) Platform, including MIS Bunion System and Furthers Global Expansion Strategy Strengthens Foot and Ankle Portfolio with Leading Minimally Invasive Surgery (MIS) Platform, including MIS Bunion System and Furthers Global Expansion Strategy

Enovis to Acquire Novastep

Esperion Therapeutics

Edgewise Therapeutics

Senseonics Holdings

SELLAS Life Sciences Group

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)

CEO Matt Trerotola to be named Chair and Director Sharon Wienbar to become Lead Independent Director following retirement of current Chair Mitchell P. Rales at 2023 Annual Meeting CEO Matt Trerotola to be named Chair and Director Sharon Wienbar to become Lead Independent Director following retirement of current Chair Mitchell P. Rales at 2023 Annual Meeting

Enovis Announces Board Leadership Transition

Medtech Leader Highlights Power of Collaboration in Its Continued Success and Innovation Medtech Leader Highlights Power of Collaboration in Its Continued Success and Innovation

ENOVIS™ Showcases Next Generation of Medical Technology at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting

Wilmington, DE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that it has been recognized as one of America's Greatest Workplaces for Diversity by Newsweek. The listing recognizes the best workplaces in the U.S. for their commitment to diversity, equity and inclusion (DEI) in the many categories of diversity.

News for Enovis Corp Stock (ENOV)